DDInter1043 DDInter1376
Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levacetylmethadol {u} (Compound) resembles {v} (Compound) Disopyramide
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Levacetylmethadol {u} (Compound) binds {v} (Gene) CYP19A1
Levacetylmethadol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenoxylate
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Doxylamine
Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Levacetylmethadol (Compound) binds CYP19A1 (Gene)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levacetylmethadol may lead to a major life threatening interaction when taken with Alvimopan
Levacetylmethadol may lead to a major life threatening interaction when taken with Naltrexone
Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Levacetylmethadol (Compound) resembles Doxylamine (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Doxylamine